Novo Nordisk

Box Reports Fiscal Fourth Quarter and Fiscal Year 2024 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Software, Technology, Networks, Apps, Applications, Cloud, Regulation, Air force, Investment, News, Part, Growth, Parent, Regulation Fair Disclosure, Novo Nordisk, Organization, Helmy Eltoukhy, FX, Marketing, Disclosure, RPO, Square, GAAP, Security (finance), Child, EPS, Microsoft, Environment, ID, Cosmetic industry, Hormel Foods, CFO, Japanese yen, FDA, Privacy, Video game

Box, Inc. (NYSE:BOX), the leading Content Cloud, today announced preliminary financial results for the fourth quarter and fiscal year 2024, which ended January 31, 2024.

Key Points: 
  • Box, Inc. (NYSE:BOX), the leading Content Cloud, today announced preliminary financial results for the fourth quarter and fiscal year 2024, which ended January 31, 2024.
  • Non-GAAP operating income in the fourth quarter of fiscal year 2024 was $70.1 million, or 26.7% of revenue.
  • Non-GAAP diluted net income per share attributable to common stockholders in the fourth quarter of fiscal year 2024 was $0.42.
  • Non-GAAP free cash flow in the fourth quarter of fiscal year 2024 was $81.8 million, a 10% increase from non-GAAP free cash flow of $74.7 million in the fourth quarter of fiscal year 2023.

Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business

Retrieved on: 
Monday, February 19, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Therapy, LNP, Acquisition, European Commission, Psoriasis, Adolescence, Immune system, Messenger, Research and development, Investment, Net, Atopic dermatitis, Growth, Drug discovery, Novo Nordisk, Safety, Human, Significance, Health care, Civil service commission, Skin, Administration, Patient, MHRA, Disease, Phase, Trial of the century, NDA, Medication, Vaccine

Net Sales of €895 MM represented year-on-year growth of 4%, driven by strong performance of the European Dermatology business.

Key Points: 
  • Net Sales of €895 MM represented year-on-year growth of 4%, driven by strong performance of the European Dermatology business.
  • Powered by our dedicated investments in launches and innovation, we achieved a 4% year-on-year growth in Net Sales, accounting for €895 MM, which was mainly driven by our European dermatology business.
  • Almirall has complemented its exciting pipeline and discovery efforts through strategic partnerships, adding long-term value to its medical dermatology portfolio.
  • The strategic focus on medical dermatology has positioned the company well for sustained growth and leadership in the medium term and beyond.

Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology

Retrieved on: 
Monday, February 19, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, BME, Dermatology, Novo Nordisk, ALM, Multimedia, Patient, Partnership, Vaccine

Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.

Key Points: 
  • Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.
  • Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases.
  • Novo Nordisk will receive an upfront payment as well as additional development and commercial milestone payments and tiered royalties based upon future global sales.
  • NN-8828 is a first-in-class in dermatology, high affinity monoclonal antibody that targets the cytokine IL-21 and has been developed by Novo Nordisk up to Phase ll in non-dermatological indications.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Retrieved on: 
Friday, March 8, 2024
Gastroesophageal reflux disease, Research, Heartburn, Blood, Diet, Cholesterol, Dietary supplement, Obesity, Dizziness, Pancreatitis, Vomiting, Health care, History, Thyroid cancer, Fatigue, Hypoglycemia, Acute kidney injury, Depression, Patient, Kidney disease, Abdominal distension, Burping, Cosmetics, Cardiovascular disease, Suicide, Weight, Stroke, Nausea, Diabetic retinopathy, Pancreas, Insulin, Blood pressure, Multimedia, Overweight, Diarrhea, Novo Nordisk, Vaccine, Safety, Heated tobacco product, Indigestion, Heart, Human services, Priority review, Division, Headache, Inflammation, FDA, Food, Weight loss, Thought, Heart rate, Gallstone, Risk, Animal, Allergy, Constipation, Death, Flatulence, Public

"This patient population has a higher risk of cardiovascular death, heart attack and stroke.

Key Points: 
  • "This patient population has a higher risk of cardiovascular death, heart attack and stroke.
  • Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
  • Obesity or overweight affect approximately 70% of American adults.
  • Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
DNA, Pfizer, Merck, Cell engineering, Forecasting, Form 10-K, Growth, Novo Nordisk, Cell, Annual report, Feedback, GAAP, Boehringer Ingelheim, Ecosystem, K-12, Video game

BOSTON, Feb. 29, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2023. The update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com.

Key Points: 
  • The update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com .
  • "2023 was a breakout year for Ginkgo," said Jason Kelly, co-founder and CEO of Ginkgo.
  • As of December 31, 2023 Ginkgo has approximately $2.4 billion in aggregate revenue potential from downstream milestone payments alone in addition to royalties.
  • There was no material downstream value share revenue received in the fourth quarter of 2023.

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases

Retrieved on: 
Monday, February 26, 2024
Therapy, Doctor of Philosophy, SAN, Diabetes, Senior, Research, Obesity, Drug discovery, Novo Nordisk, Conditional sentence, Entrepreneurship, Health, Pharmaceutical industry

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders.

Key Points: 
  • SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders.
  • "We are incredibly excited to partner with Novo Nordisk, a world-class healthcare company within diabetes, obesity and rare blood disorders," said Phil Chamberlain, DPhil, Co-Founder, President, and CEO of Neomorph.
  • "By combining Neomorph's proprietary glue discovery platform with Novo Nordisk's vast experience in cardiometabolic and rare diseases, we are well positioned to develop transformative treatments in these areas.
  • We are pleased to enter this research collaboration and eager to start the scientific work on the novel class of molecular glue degraders being pioneered by Neomorph," said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk.

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases

Retrieved on: 
Monday, February 26, 2024
Therapy, Doctor of Philosophy, SAN, Diabetes, Senior, Research, Obesity, Drug discovery, Novo Nordisk, Conditional sentence, Entrepreneurship, Health, Pharmaceutical industry

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders.

Key Points: 
  • SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders.
  • "We are incredibly excited to partner with Novo Nordisk, a world-class healthcare company within diabetes, obesity and rare blood disorders," said Phil Chamberlain, DPhil, Co-Founder, President, and CEO of Neomorph.
  • "By combining Neomorph's proprietary glue discovery platform with Novo Nordisk's vast experience in cardiometabolic and rare diseases, we are well positioned to develop transformative treatments in these areas.
  • We are pleased to enter this research collaboration and eager to start the scientific work on the novel class of molecular glue degraders being pioneered by Neomorph," said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk.

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Retrieved on: 
Thursday, February 15, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Therapy, Fast Track, Acquisition, SAD, VITAL, Roche, American Society of Hematology, ASH, Risk, Food, Epitope, AAIC, ID, Novo Nordisk, Exercise, Organ dysfunction, Amyloidosis, Amyloid, Conference, Bristol Myers Squibb, BMS, Society, TTR, European Medicines Agency, Patient, Clinical trial, ATTR, IND, Orphan, Mortality, Failure, Pharmaceutical industry

In addition, the Company provided 2024 financial guidance and business highlights.

Key Points: 
  • In addition, the Company provided 2024 financial guidance and business highlights.
  • “2023 was a year of strong progress for Prothena as we advanced our protein dysregulation portfolio and moved closer to becoming a fully integrated commercial company.
  • Total revenue for the fourth quarter and full year of 2023 included BMS collaboration revenue of $0.3 million and $91.3 million, respectively.
  • As of December 31, 2023, Prothena had $621.0 million in cash, cash equivalents and restricted cash, and no debt.

Acarix Strengthens U.S. Team with Three Key Advisors

Retrieved on: 
Thursday, February 15, 2024
Biotelemetry, Boston Scientific, Cardiology, Novo Nordisk, Medtech, Knowledge, Publication

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors to its team.

Key Points: 
  • NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors to its team.
  • Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors.
  • His clinical and business expertise will provide the Acarix team with a fresh new viewpoint of the U.S. market.
  • "I am pleased to welcome Mr. Nelson, Dr. Oza, and Mr. Braun to the Acarix team," stated Aamir Mahmood, President & CEO of Acarix.

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT

Retrieved on: 
Wednesday, February 14, 2024
Class Action Lawsuit, Professional Services, Legal, Titan, Eli Lilly, Report, News, ALT, Novo Nordisk, Advertising, Patient

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.